Cargando…

Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease

Vision-threatening retinal diseases affect millions of people worldwide, representing an important public health issue (high social cost) for both technologically advanced and new-industrialized countries. Overall RD group comprises the retinitis pigmentosa, the age-related macular degeneration (AMD...

Descripción completa

Detalles Bibliográficos
Autores principales: Micera, Alessandra, Balzamino, Bijorn Omar, Di Zazzo, Antonio, Dinice, Lucia, Bonini, Stefano, Coassin, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873955/
https://www.ncbi.nlm.nih.gov/pubmed/33584278
http://dx.doi.org/10.3389/fphar.2020.601647
_version_ 1783649485304365056
author Micera, Alessandra
Balzamino, Bijorn Omar
Di Zazzo, Antonio
Dinice, Lucia
Bonini, Stefano
Coassin, Marco
author_facet Micera, Alessandra
Balzamino, Bijorn Omar
Di Zazzo, Antonio
Dinice, Lucia
Bonini, Stefano
Coassin, Marco
author_sort Micera, Alessandra
collection PubMed
description Vision-threatening retinal diseases affect millions of people worldwide, representing an important public health issue (high social cost) for both technologically advanced and new-industrialized countries. Overall RD group comprises the retinitis pigmentosa, the age-related macular degeneration (AMD), the diabetic retinopathy (DR), and idiopathic epiretinal membrane formation. Endocrine, metabolic, and even lifestyles risk factors have been reported for these age-linked conditions that represent a “public priority” also in this COVID-19 emergency. Chronic inflammation and neurodegeneration characterize the disease evolution, with a consistent vitreoretinal interface impairment. As the vitreous chamber is significantly involved, the latest diagnostic technologies of imaging (retina) and biomarker detection (vitreous) have provided a huge input at both medical and surgical levels. Complement activation and immune cell recruitment/infiltration as well as detrimental intra/extracellular deposits occur in association with a reactive gliosis. The cell/tissue aging route shows a specific signal path and biomolecular profile characterized by the increased expression of several glial-derived mediators, including angiogenic/angiostatic, neurogenic, and stress-related factors (oxidative stress metabolites, inflammation, and even amyloid formation). The possibility to access vitreous chamber by collecting vitreous reflux during intravitreal injection or obtaining vitreous biopsy during a vitrectomy represents a step forward for an individualized therapy. As drug response and protein signature appear unique in each single patient, therapies should be individualized. This review addresses the current knowledge about biomarkers and pharmacological targets in these vitreoretinal diseases. As vitreous fluids might reflect the early stages of retinal sufferance and/or late stages of neurodegeneration, the possibility to modulate intravitreal levels of growth factors, in combination to anti-VEGF therapy, would open to a personalized therapy of retinal diseases.
format Online
Article
Text
id pubmed-7873955
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78739552021-02-11 Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease Micera, Alessandra Balzamino, Bijorn Omar Di Zazzo, Antonio Dinice, Lucia Bonini, Stefano Coassin, Marco Front Pharmacol Pharmacology Vision-threatening retinal diseases affect millions of people worldwide, representing an important public health issue (high social cost) for both technologically advanced and new-industrialized countries. Overall RD group comprises the retinitis pigmentosa, the age-related macular degeneration (AMD), the diabetic retinopathy (DR), and idiopathic epiretinal membrane formation. Endocrine, metabolic, and even lifestyles risk factors have been reported for these age-linked conditions that represent a “public priority” also in this COVID-19 emergency. Chronic inflammation and neurodegeneration characterize the disease evolution, with a consistent vitreoretinal interface impairment. As the vitreous chamber is significantly involved, the latest diagnostic technologies of imaging (retina) and biomarker detection (vitreous) have provided a huge input at both medical and surgical levels. Complement activation and immune cell recruitment/infiltration as well as detrimental intra/extracellular deposits occur in association with a reactive gliosis. The cell/tissue aging route shows a specific signal path and biomolecular profile characterized by the increased expression of several glial-derived mediators, including angiogenic/angiostatic, neurogenic, and stress-related factors (oxidative stress metabolites, inflammation, and even amyloid formation). The possibility to access vitreous chamber by collecting vitreous reflux during intravitreal injection or obtaining vitreous biopsy during a vitrectomy represents a step forward for an individualized therapy. As drug response and protein signature appear unique in each single patient, therapies should be individualized. This review addresses the current knowledge about biomarkers and pharmacological targets in these vitreoretinal diseases. As vitreous fluids might reflect the early stages of retinal sufferance and/or late stages of neurodegeneration, the possibility to modulate intravitreal levels of growth factors, in combination to anti-VEGF therapy, would open to a personalized therapy of retinal diseases. Frontiers Media S.A. 2021-01-18 /pmc/articles/PMC7873955/ /pubmed/33584278 http://dx.doi.org/10.3389/fphar.2020.601647 Text en Copyright © 2021 Micera, Balzamino, Di Zazzo, Dinice, Bonini and Coassin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Micera, Alessandra
Balzamino, Bijorn Omar
Di Zazzo, Antonio
Dinice, Lucia
Bonini, Stefano
Coassin, Marco
Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease
title Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease
title_full Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease
title_fullStr Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease
title_full_unstemmed Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease
title_short Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease
title_sort biomarkers of neurodegeneration and precision therapy in retinal disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873955/
https://www.ncbi.nlm.nih.gov/pubmed/33584278
http://dx.doi.org/10.3389/fphar.2020.601647
work_keys_str_mv AT miceraalessandra biomarkersofneurodegenerationandprecisiontherapyinretinaldisease
AT balzaminobijornomar biomarkersofneurodegenerationandprecisiontherapyinretinaldisease
AT dizazzoantonio biomarkersofneurodegenerationandprecisiontherapyinretinaldisease
AT dinicelucia biomarkersofneurodegenerationandprecisiontherapyinretinaldisease
AT boninistefano biomarkersofneurodegenerationandprecisiontherapyinretinaldisease
AT coassinmarco biomarkersofneurodegenerationandprecisiontherapyinretinaldisease